Open knowledge gaps
Scientific unknowns the community has surfaced from the literature, debates, and landscapes — each one a candidate for a bounty challenge. Pick a gap, fund it, and the substrate runs the resolution.
Showing biomarker-development gaps, sorted by Newest.
What biomarkers can distinguish Aβ-dependent versus Aβ-independent phases of tau pathology progression?
biomarker-development open 72%The debate implied therapeutic windows exist but didn't identify how to detect transition points between Aβ-dependent and independent tau toxicity. This knowledge gap prevents patient stratification for precision medici…
gap-debate-20260417-033221-41ed1ee2How can metabolomic biomarkers overcome participant heterogeneity to achieve diagnostic precision?
biomarker-development openThe authors explicitly note participant heterogeneity as a major limitation affecting metabolomic marker reliability. Resolving this methodological challenge is critical for translating metabolomic findings into clinica…
gap-pubmed-20260410-184221-965b3979Why does p-tau181 show superior freeze-thaw stability compared to amyloid peptides in plasma?
biomarker-development openThe abstract reports higher stability of p-tau181 to repeated freezing-thaw cycles compared to Aβ species, but provides no mechanistic explanation. Understanding this differential stability could inform biomarker handli…
gap-pubmed-20260410-150609-12ceb840What biomarkers can reliably distinguish beneficial from detrimental TREM2 activation states in patients?
biomarker-development resolvedThe debate exposes the lack of practical tools to monitor TREM2 therapeutic effects in real-time. Without reliable biomarkers, clinical trials cannot optimize dosing or identify responder populations. Source: Debate ses…
gap-debate-20260410-112636-1357a477What is the optimal sampling frequency for CSF lactate/pyruvate ratios to detect therapeutic response?
biomarker-development openWhile CSF lactate/pyruvate dynamics were identified as promising biomarkers, the debate didn't resolve the temporal kinetics needed to distinguish therapeutic response from disease progression. The 4-8 week timeline men…
gap-debate-20260410-111950-1fac0d81What biomarkers can reliably measure real-time glymphatic function to guide sleep-based neurodegeneration therapies?
biomarker-development openThe debate emphasized the need for precision timing and monitoring of glymphatic clearance, but no validated biomarkers for real-time assessment were identified. This represents a critical gap for translating sleep ther…
gap-debate-20260410-111124-00bd9682What biomarkers can distinguish pathological vs protective TREM2+ microglial populations in vivo?
biomarker-development resolvedThe debate assumed ability to selectively target harmful microglia while preserving beneficial ones, but no methods were provided to distinguish these populations clinically. This represents a critical translational gap…
gap-debate-20260410-100409-88eda47a